Immix Biopharma (IMMX) Common Equity (2020 - 2026)

Immix Biopharma has disclosed Common Equity across 7 years of filings, most recently posting $84.4 million for Q1 2026.

• Common Equity for Q1 2026 came in at $84.4 million, up 779.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $84.4 million (up 779.38% YoY), and the FY2025 annual result was $93.8 million, up 607.83% from the prior year.
• Common Equity came in at $84.4 million for Q1 2026 at Immix Biopharma, down from $93.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $93.8 million in Q4 2025 to a low of $4.7 million in Q2 2025.
• The 5-year median for Common Equity is $16.7 million (2022), against an average of $24.2 million.
• Across the five-year window, Common Equity plunged 80.52% in 2025 and jumped 779.38% in 2026, its largest moves.
• Immix Biopharma's Common Equity stood at $13.2 million in 2022, then advanced by 23.13% to $16.2 million in 2023, then retreated by 18.22% to $13.3 million in 2024, then surged by 607.83% to $93.8 million in 2025, then slipped by 10.06% to $84.4 million in 2026.
• The last three Common Equity figures came in at $84.4 million (Q1 2026), $93.8 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.